Literature DB >> 22790124

Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients: a cross-sectional study.

Yuichiro Takeuchi1, Hiroyuki Ito, Yuko Komatsu, Koshiro Oshikiri, Shinichi Antoku, Mariko Abe, Mizuo Mifune, Michiko Togane.   

Abstract

OBJECTIVE: To clarify the clinical characteristics of type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD) and to assess whether NAFLD is related to angiopathy.
METHODS: The study included 388 Japanese type 2 diabetic outpatients without viral hepatitis. The main outcome measures were angiopathy and NAFLD.
RESULTS: The 388 subjects were divided into two subgroups based on alcohol consumption. Fatty liver was recognized in 36 of the 142 drinking patients (25%). There was no association of fatty liver disease with diabetic macro- or microangiopathy in these patients. Fatty liver disease (namely, NAFLD) was recognized in 77 of the 246 non-drinking patients (31%). Type 2 diabetic patients with NAFLD had a significantly younger age, higher body mass index level, higher levels of HbA1c, total cholesterol and triglyceride, lower HDL-C level, higher prevalence rates of hypercholesterolemia and obesity than counterparts without NAFLD. In addition, individuals in the elderly (≥65 years) non-drinking group with NAFLD had a significantly higher prevalence rates of diabetic macroangiopathy, coronary heart disease and thicker intima-media thickness level than their counterparts without NAFLD. The logistic regression analysis showed that NAFLD is an independent predictor of diabetic macroangiopathy.
CONCLUSION: NAFLD was associated with an increased prevalence of diabetic macroangiopathy and coronary heart disease in elderly patients. In addition, NAFLD is an independent predictor for diabetic macroangiopathy. These findings suggest that type 2 diabetic patients with NAFLD should be considered as a high risk group for developing macroangiopathy, even if macroangiopathy is not clinically detected.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22790124     DOI: 10.2169/internalmedicine.51.7307

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus.

Authors:  Ryosuke Yamane; Kentaro Yoshioka; Kazuhiko Hayashi; Yuko Shimizu; Yuki Ito; Komei Matsushita; Michiyo Yoshizaki; Go Kajikawa; Taro Mizutani; Atsuko Watarai; Kosuke Tachi; Hidemi Goto
Journal:  World J Hepatol       Date:  2022-06-27

Review 2.  The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.

Authors:  Cyrielle Caussy; Adrien Aubin; Rohit Loomba
Journal:  Curr Diab Rep       Date:  2021-03-19       Impact factor: 4.810

3.  Nonalcoholic fatty liver disease is associated with low HDL cholesterol and coronary angioplasty in patients with type 2 diabetes.

Authors:  Aleksandra Trojak; Małgorzata Waluś-Miarka; Ewa Woźniakiewicz; Maciej T Małecki; Barbara Idzior-Waluś
Journal:  Med Sci Monit       Date:  2013-12-16

4.  Association of [1H]-MRS quantified liver fat content with glucose metabolism status.

Authors:  Yun-Sheng Wang; Jun Ye; Yong-Hong Cao; Rong Zhang; Xiao-Fang Han; Ling-Ling Zou; Lei Kuang; Ji Zhang; Hu Lian; Jin-Xiang Xia; Qiu Zhang; Wu Dai
Journal:  Diabetol Metab Syndr       Date:  2020-06-08       Impact factor: 3.320

5.  Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  Qiumei Zhou; Yulong Wang; Jiajia Wang; Yating Liu; Dehui Qi; Wei Yao; Hui Jiang; Tingting Li; Kaiquan Huang; Wancun Zhang; Xingxing Huo
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

6.  DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus.

Authors:  Ippei Kanazawa; Ken-ichiro Tanaka; Toshitsugu Sugimoto
Journal:  Med Sci Monit       Date:  2014-09-17

7.  Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.

Authors:  Guoyu Jia; Fusheng Di; Qipeng Wang; Jinshuang Shao; Lei Gao; Lu Wang; Qiang Li; Nali Li
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.